FGFR3 is altered in 27.83% of urothelial carcinoma patients [3].

FGFR3 is an inclusion criterion in 16 clinical trials for urothelial carcinoma, of which 13 are open and 3 are closed. Of the trials that contain FGFR3 status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 7 are phase 1/phase 2 (6 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (0 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [4].

Erdafitinib has evidence of efficacy in patients with FGFR3 mutation in urothelial carcinoma [4].

FGFR3 is altered in 25.0% of bladder carcinoma patients [3].

FGFR3 is an inclusion criterion in 6 clinical trials for bladder carcinoma, of which 4 are open and 2 are closed. Of the trials that contain FGFR3 status and bladder carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (1 open), and 1 is no phase specified (1 open) [4].

Erdafitinib has evidence of efficacy in patients with FGFR3 mutation in bladder carcinoma [4].

FGFR3 is altered in 2.89% of multiple myeloma patients [3].

FGFR3 is an inclusion criterion in 31 clinical trials for multiple myeloma, of which 22 are open and 9 are closed. Of the trials that contain FGFR3 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (5 open), 5 are phase 1/phase 2 (4 open), and 17 are phase 2 (12 open) [4].

FGFR3 is altered in 2.65% of malignant solid tumor patients [3].

FGFR3 is an inclusion criterion in 25 clinical trials for malignant solid tumor, of which 18 are open and 7 are closed. Of the trials that contain FGFR3 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (1 open), 5 are phase 1/phase 2 (4 open), 12 are phase 2 (12 open), and 1 is phase 4 (1 open) [4].

FGFR3 is an inclusion criterion in 11 clinical trials for acute lymphoblastic leukemia, of which 9 are open and 2 are closed. Of the trials that contain FGFR3 status and acute lymphoblastic leukemia as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), and 1 is phase 2/phase 3 (1 open) [4].

FGFR3 is an inclusion criterion in 10 clinical trials for plasma cell leukemia, of which 5 are open and 5 are closed. Of the trials that contain FGFR3 status and plasma cell leukemia as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 7 are phase 2 (4 open) [4].

FGFR3 is altered in 1.54% of breast carcinoma patients [3].

FGFR3 is an inclusion criterion in 7 clinical trials for breast carcinoma, of which 6 are open and 1 is closed. Of the trials that contain FGFR3 status and breast carcinoma as inclusion criteria, 5 are phase 1 (4 open) and 2 are phase 2 (2 open) [4].

FGFR3 is altered in 0.32% of acute myeloid leukemia patients [3].

FGFR3 is an inclusion criterion in 7 clinical trials for acute myeloid leukemia, of which 6 are open and 1 is closed. Of the trials that contain FGFR3 status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

FGFR3 is altered in 2.17% of cholangiocarcinoma patients [3].

FGFR3 is an inclusion criterion in 6 clinical trials for cholangiocarcinoma, of which 6 are open and 0 are closed. Of the trials that contain FGFR3 status and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

FGFR3 is altered in 1.48% of non-small cell lung carcinoma patients [3].

FGFR3 is an inclusion criterion in 6 clinical trials for non-small cell lung carcinoma, of which 5 are open and 1 is closed. Of the trials that contain FGFR3 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 5 are phase 2 (4 open) [4].

FGFR3 is altered in 0.28% of myelodysplastic syndromes patients [3].

FGFR3 is an inclusion criterion in 6 clinical trials for myelodysplastic syndromes, of which 5 are open and 1 is closed. Of the trials that contain FGFR3 status and myelodysplastic syndromes as inclusion criteria, 3 are phase 1 (2 open) and 3 are phase 2 (3 open) [4].

FGFR3 is altered in 2.53% of cancer patients [3].

FGFR3 is an inclusion criterion in 5 clinical trials for cancer, of which 1 is open and 4 are closed. Of the trials that contain FGFR3 status and cancer as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (1 open) [4].

FGFR3 is altered in 1.36% of non-hodgkin lymphoma patients [3].

FGFR3 is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 5 are open and 0 are closed. Of the trials that contain FGFR3 status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (2 open) [4].

FGFR3 is an inclusion criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain FGFR3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [4].

FGFR3 is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain FGFR3 status and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 4 clinical trials for chronic myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain FGFR3 status and chronic myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 4 clinical trials for smoldering plasma cell myeloma, of which 3 are open and 1 is closed. Of the trials that contain FGFR3 status and smoldering plasma cell myeloma as inclusion criteria, 3 are phase 2 (2 open) and 1 is phase 3 (1 open) [4].

FGFR3 is altered in 27.83% of transitional cell carcinoma patients [3].

FGFR3 is an inclusion criterion in 3 clinical trials for transitional cell carcinoma, of which 0 are open and 3 are closed. Of the trials that contain FGFR3 status and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (0 open), and 1 is phase 2/phase 3 (0 open) [4].

FGFR3 is altered in 4.23% of endometrial carcinoma patients [3].

FGFR3 is an inclusion criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

FGFR3 is altered in 2.92% of squamous cell lung carcinoma patients [3].

FGFR3 is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [4].

FGFR3 is altered in 1.98% of gastric carcinoma patients [3].

FGFR3 is an inclusion criterion in 3 clinical trials for gastric carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

FGFR3 is altered in 1.39% of adenocarcinoma of the gastroesophageal junction patients [3].

FGFR3 is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

FGFR3 is an inclusion criterion in 3 clinical trials for chronic myelomonocytic leukemia, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 status and chronic myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

FGFR3 is altered in 26.68% of bladder urothelial carcinoma patients [3].

FGFR3 is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR3 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2/phase 3 (0 open) [4].

FGFR3 is altered in 3.25% of head and neck squamous cell carcinoma patients [3].

FGFR3 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR3 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

FGFR3 is altered in 2.63% of colorectal carcinoma patients [3].

FGFR3 is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and colorectal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

FGFR3 is altered in 1.99% of gastric adenocarcinoma patients [3].

FGFR3 is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

FGFR3 is altered in 1.35% of sarcoma patients [3].

FGFR3 is an inclusion criterion in 2 clinical trials for sarcoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

FGFR3 is altered in 1.29% of lymphoma patients [3].

FGFR3 is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR3 status and lymphoma as inclusion criteria, 2 are phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 2 clinical trials for hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [4].

FGFR3 is an inclusion criterion in 2 clinical trials for lymphoblastic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2/phase 3 (1 open) [4].

FGFR3 is an inclusion criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [4].

FGFR3 is an inclusion criterion in 2 clinical trials for myeloproliferative neoplasm, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 2 clinical trials for non-muscle invasive bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and non-muscle invasive bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

FGFR3 is altered in 33.22% of infiltrating renal pelvis and ureter urothelial carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for infiltrating renal pelvis and ureter urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and infiltrating renal pelvis and ureter urothelial carcinoma as inclusion criteria, 1 is phase 2/phase 3 (0 open) [4].

FGFR3 is altered in 33.33% of urethral urothelial carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for urethral urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and urethral urothelial carcinoma as inclusion criteria, 1 is phase 2/phase 3 (0 open) [4].

FGFR3 is altered in 6.67% of pilomyxoid astrocytoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is altered in 4.44% of anaplastic oligodendroglioma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is altered in 4.68% of oropharyngeal squamous cell carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 3.43% of melanoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 3.27% of oral cavity carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 3.27% of oral cavity squamous cell carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 3.57% of malignant uterine neoplasm patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 3.58% of small cell lung carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

FGFR3 is altered in 3.23% of anaplastic astrocytoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is altered in 3.27% of extrahepatic cholangiocarcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is altered in 3.72% of glioblastoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is altered in 2.33% of head and neck carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 3.51% of malignant glioma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [4].

FGFR3 is altered in 2.89% of myeloma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for myeloma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 3.28% of astrocytic tumor patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is altered in 3.21% of diffuse glioma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is altered in 2.98% of glioma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and glioma as inclusion criteria, 1 is phase 2 (0 open) [4].

FGFR3 is altered in 2.14% of gallbladder carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 1.23% of laryngeal squamous cell carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 2.17% of bile duct carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 1.98% of low grade glioma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is altered in 1.12% of ganglioglioma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is altered in 1.96% of ovarian carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 1.55% of lung carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 2.02% of intrahepatic cholangiocarcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is altered in 2.47% of cervical carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 1.45% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FGFR3 is altered in 1.18% of soft tissue sarcoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 1.7% of diffuse large B-cell lymphoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FGFR3 is altered in 1.54% of invasive breast carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and invasive breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

FGFR3 is altered in 1.49% of histiocytic and dendritic cell neoplasm patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 1.2% of pancreatic carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 1.37% of B-cell non-hodgkin lymphoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 2.04% of esophageal squamous cell carcinoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 1.28% of lymphocytic neoplasm patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for lymphocytic neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and lymphocytic neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 1.23% of pilocytic astrocytoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is altered in 1.16% of neuronal and mixed neuronal-glial tumors patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is altered in 1.12% of mantle cell lymphoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FGFR3 is altered in 0.77% of gastrointestinal stromal tumor patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 0.29% of myeloid neoplasm patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is altered in 0.51% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [3].

FGFR3 is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and double-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for plasmacytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and plasmacytoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for prolymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for renal pelvis urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and renal pelvis urothelial carcinoma as inclusion criteria, 1 is phase 2/phase 3 (0 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for small lymphocytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and small lymphocytic lymphoma as inclusion criteria, 1 is phase 2 (0 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for T-cell prolymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for ureter urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and ureter urothelial carcinoma as inclusion criteria, 1 is phase 2/phase 3 (0 open) [4].

FGFR3 is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 2 (0 open) [4].